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Abstract: The main source of n-3 long-chain polyunsaturated fatty acids (LC-PUFA) in 
human nutrition is currently seafood, especially oily fish. Nonetheless, due to cultural or 
individual preferences, convenience, geographic location, or awareness of risks associated 
to fatty fish consumption, the intake of fatty fish is far from supplying the recommended 
dietary levels. The end result observed in most western countries is not only a low supply 
of n-3 LC-PUFA, but also an unbalance towards the intake of n-6 fatty acids, resulting 
mostly from the consumption of vegetable oils. Awareness of the benefits of LC-PUFA in 
human health has led to the use of fish oils as food supplements. However, there is a need 
to explore alternatives sources of LC-PUFA, especially those of microbial origin. 
Microalgae species with potential to accumulate lipids in high amounts and to present 
elevated levels of n-3 LC-PUFA are known in marine phytoplankton. This review focuses 
on sources of n-3 LC-PUFA, namely eicosapentaenoic and docosahexaenoic acids, in 
marine microalgae, as alternatives to fish oils. Based on current literature, examples of 
marketed products and potentially new species for commercial exploitation are presented. 
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1. Introduction 
Research on microalgal lipids has gathered significant interest over the last few years, not only due 
to their bioactive properties, but also as an important component of aquaculture feed, feedstock for the 
production of biofuels, and energy and biomass transfer between different trophic levels in the global 
food web [1–3]. This review will focus on the long-chain polyunsaturated fatty acids (LC-PUFA), their 
role in promoting human health or disease, and the dire need for alternative sources of LC-PUFA able 
to replace fish meal/oil as the bulk provider for this important class of biochemicals. Although a few 
topics have been covered elsewhere [4–7], this review integrates the current knowledge on microalgal 
LC-PUFA biosynthesis and the use of specific examples of commercial photo- and heterotrophic 
microalgae for the production of fatty acids (FA) that can have an impact on the health of humans and 
other vertebrates. Lastly, this review discusses the methods usually employed in LC-PUFA 
quantitation and the care needed for preventing LC-PUFA depletion upon microalgal cell disruption, 
which could lead to incorrect fatty acid profiles. 
2. Long Chain Polyunsaturated Fatty Acids and Their Importance in Human Health 
The importance of diet to physical and mental wellbeing has gained increased attention from the 
medical community and the public in the last decades. The dietary intake of LC-PUFA, particularly the 
n-3 series eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), occurs mainly through seafood 
consumption, and is typically low in the so-called “western” diet [8]. The relevance of these nutrients 
was first highlighted when populations with frequent seafood consumption habits (e.g., Inuits) were 
noted to present a lower incidence of cardiovascular diseases (CVD) relative to others consuming less 
seafood and more n-6 PUFA, C18 fatty acids, mainly linoleic acid (LA) [9,10]. At present, most 
western populations consume an average of less than 0.5 g of n-3 LC-PUFA daily, lower than values 
determined for Japan and Norway (1–3 g daily), and much lower than the intake of these nutrients by 
Inuit populations, which amount to 10–14 g day
−1
 [8]. Most health benefits of seafood consumption are 
attributed to EPA and DHA. Nonetheless, these foods are also rich sources of other nutrients, such as 
high quality protein, various vitamins (e.g., A, D, B12) and minerals (e.g., iodine and selenium), and 
other bioactive compounds, including carotenoids with antioxidant properties (e.g., astaxanthin), 
phytosterols related with hypocholesterolemic effects, and the amino acid taurine, linked to 
cardioprotective effects [11]. 
Throughout evolution, the human diet was characterized by a practically even supply of n-3 and n-6 
PUFA, which have played a role in the establishment of genetic patterns (reviewed by Leaf and  
Weber [12]). However, a significant increase in dietary content of n-6 PUFA along with lower n-3 
PUFA has occurred during the last 100 years, especially in western societies, resulting in n-6:n-3 
PUFA ratios of about 15 to 20, which can promote the pathogenesis of many diseases, such as 
coronary heart disease (CHD), as suggested by observational and interventional studies [13–15]. 
Indeed, LC-PUFA intake is often dominated by n-6 fatty acids, which have been correlated with higher 
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CHD mortality, whereas ideally those should represent only about 20%–40% of total dietary  
LC-PUFA [14,16,17]. In practice, in 2008, experts from the Food and Agriculture Organization and 
the World Health Organization (Joint WHO/FAO Expert Consultation on Fats and Fatty Acids in 
Human Nutrition, Geneva, Switzerland) recommended the daily intake of 250 mg EPA plus DHA in 
primary prevention, whereas the American Heart Association (AHA) proposed a higher daily dosage 
(500 mg) for healthy adults [18]. Intake values mentioned for individuals with documented CHD vary 
between 1 and 2 g per day, whereas up to 4 g EPA and DHA daily have been suggested for 
hypertriglyceridemic adults [19]. It has been considered by WHO/FAO that convincing evidence exists 
showing daily consumption of 250 mg (primary prevention) to 2 g (secondary prevention) of EPA and 
DHA prevents CHD and possibly other degenerative diseases associated with aging, and decreases the 
risk of fatal CHD events. Although at present the upper level of acceptable micronutrient distribution 
rate set by WHO/FAO is at 2 g for EPA plus DHA to prevent potential increase in lipid peroxidation, 
the USA Food and Drug Administration (FDA) has set as safe intake values of 3 g day
−1
, and the 
former entities have also acknowledged that further research could justify raising the recommended 
intake value for n-3 LC-PUFA in the future. Secondary prevention studies using 850 mg to 4 g EPA 
and DHA daily have shown significantly reduced total mortality and sudden death (20%–50%) with 
treatments from 12 to 42 months duration, in patients with CHD or prior myocardial infarction 
(reviewed by Jacobson [20]). It should be noted that clinical intervention trials involving n-3 LC-PUFA 
intake during limited periods show limited cardiovascular benefits when compared to results from 
epidemiological studies with populations characterized by a lifetime of consuming diets high in these 
nutrients [21]. Moreover, variation of the effects of supplementation on primary and secondary 
prevention of CHD among studies is affected by several factors, including background diet, 
supplementation means, genetic factors and ethnicity [22]. 
Several other fields of medicine have explored the potential of these nutrients. They have been 
implied in the prevention of age-associated decline in cognition, and addressed in the treatment of 
psychiatric conditions and neurological disorders [23,24]. Cancer research has shown promising results 
regarding the potential of n-3 LC-PUFA in prevention, antitumor effects, adjuvant activity with 
anticancer drugs, and reduction of cancer therapy-related side effects [25,26]. Another special focus is 
on fetal neurodevelopment, infant cognitive development and visual acuity, which have been related to 
maternal seafood consumption and n-3 LC-PUFA supply, especially DHA during early life [27,28]. 
Although it is generally accepted that n-3 LC-PUFA play a central role in cell membrane structure and 
function, cellular signaling and overall physiology, the mechanisms that may lead to a lower 
occurrence of CVD and other pathologies are yet to be clarified. Fatty acids containing 20 and  
22 carbon atoms in their chain, like EPA, arachidonic acid (AA; n-6 LC-PUFA), and DHA serve as 
precursors of eicosanoids (prostaglandins, leukotrienes and thromboxanes). Polyunsaturates and their 
metabolites are seen with interest by the pharmaceutical industry. They can cause pleiotropic effects in 
terms of blood rheology, leukocyte function, platelet activation and lipoprotein metabolism, as well as 
physiological mechanisms like inflammation, vasodilation, blood pressure, pain and fever [29,30]. 
EPA and DHA are associated with anti-inflammatory effects and may present antiarrhythmic, 
antithrombotic and antiatherosclerotic properties, improve endothelial function, display mild 
hypotensive effects, and contribute to reduce blood cholesterol and triacylglycerol (TAG) levels; they 
may also show hypoglycemic effects [20,21,31]. Since EPA- and AA-derived eicosanoids generally 
Mar. Drugs 2013, 11 2262 
 
 
present antagonistic effects, their ratio in tissues, largely dependent on dietary supply, can be often 
related to cellular signaling, metabolic and health outcomes (reviewed by Simopoulos [13]).  
Over-reactions mediated by n-6 eicosanoids represent main targets for therapeutic drugs, and primary 
prevention with greater dietary proportions of n-3 LC-PUFA may decrease the need for medication [14]. 
Although more relevance is generally given to supplements delivering n-3 LC-PUFA, in order to 
balance the dietary ratios between n-6 and n-3 fatty acids, it is generally recommended that formula-fed 
pre-term infants should include AA as well as DHA, which deposit rapidly in fetal neural tissue during 
the last months of gestation and the first months of postnatal life. Dietary supply of pre-formed AA 
and DHA is more likely to meet the requirements of developing tissues, due to limited Δ-6 desaturase 
activity in humans. In this regard, governmental food safety authorities have determined the safety and 
approved the use of DHA and AA rich-oils extracted from the single cell organisms  
Crypthecodinium cohnii Javornicky, a marine heterotrophic microalga, and Mortierella alpina 
Peyronel, a soil fungus, respectively, for inclusion as supplements in infant formulas [32]. However, 
the use of single cell oils may be costly and oils richer in other fatty acids with important physiological 
roles (e.g., oleic and linoleic acids serving as energy substrates) may still be used in infant formulas. 
Along with fish oils, microbial oils like those cited have been approved for inclusion in adult foods, 
including pregnant and nursing women. In particular, vegetarian breast-feeding mothers may benefit 
from AA supplementation, since this fatty acid is mainly found in animal-based foods (meats, eggs). 
Negative effects of elevated LC-PUFA intake may stem from their susceptibility to peroxidation 
due to high unsaturation degree, and is more likely to occur when antioxidant enzyme activity and 
micronutrients are lower. Therefore, antioxidant micronutrients (e.g., vitamins E and C, and selenium) 
are often advised when LC-PUFA supplementation is considered. Whichever their origin, the oxidative 
instability of LC-PUFA-rich oils requires special attention in order to keep their nutritional quality and 
avoid the development of off-flavors in final products. When used as food ingredients, the stability of 
oils may benefit from microencapsulation techniques, the use of antioxidants, and adapted food 
processing methods [33]. 
3. LC n-3 PUFA Sources: The Need for Alternatives 
Due to convenience, dietary preferences and other factors, the ability to assess n-3 LC-PUFA 
through supplements or enriched foods is of great interest for most populations with diets low in 
seafood. According to a review by Ward and Singh [6], a daily dietary intake of 1 g DHA and EPA in 
seafood would require the consumption of a great amount of fish. Health risks have been associated to 
the consumption of seafood and fish oils at times, in particular areas, and regarding certain species, and 
often drive consumers choices away from these products. Indeed, fatty fish and large predatory fish are 
sometimes the subject of health advisories against the risks of contamination with environmental 
pollutants (e.g., methyl mercury, dioxins and polychlorinated biphenyls), which are hydrophobic and 
accumulate along the marine food chain, particularly in lipid depots [34]. Under certain conditions, 
seafood originating from contaminated regions may be hazardous for humans, particularly pregnant or 
lactating women and young children, such that advisories to limit consumption of certain types of 
seafood are released. However, it is generally recognized that, with the exception of a few top predator 
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species, from particularly polluted regions, the benefits provided by seafood to most consumers far 
outweigh the risks [35,36]. 
As ingredients for the enrichment of various foods, fish oils show traits that can be found 
undesirable, the typical odor presenting as a disadvantage for many consumers. Due to odor or  
off-flavors sometimes derived from lipid peroxidation, these foods may in certain cases lose sensory 
quality and show a decreased shelf life [37]. At present, they are still the main utilized source of EPA 
and DHA in n-3 LC-PUFA-enriched functional foods. Nonetheless, the market for marine fish oils is 
largely dominated by the aquaculture industry for use as a main lipid ingredient in feeds for farmed 
fish. The sustainability of fisheries directed for this purpose has become a major concern as global 
catches have attained a maximum limit since the 80’s [38]. The availability of this product is affected 
periodically by environmental conditions, which further contributes to significant rises in the price of 
this commodity. 
The need for sustainable, alternative n-3 LC-PUFA sources has stimulated research in several 
fields. Cellular and molecular methodologies exist that allow the introduction or increased expression 
of genes for the enzymatic machinery involved in desaturation and elongation of shorter chain fatty 
acids into LC-PUFA. The potential of plants and animals to biosynthesize these nutrients through 
genetic manipulation, with the aim to increase the amount of desired fatty acids in their lipid profiles, 
is currently under investigation with the production of transgenic oilseed crops [39,40] and animals [41,42]. 
While important advances have been made on the production of oils from transgenic plants, the 
commercial use of genetically manipulated products in food and feed is the focus of much scientific 
and social debate and may be delayed due to common negative public perception over this subject. 
On the other hand, functional foods enriched with n-3 LC-PUFA from either fish or microbial 
origin, are generally perceived as interesting by consumers [33], as their belief on the effectiveness of 
these products to deliver important health benefits has increased in recent years [43]. Hence, the n-3 
LC-PUFA supplemented food sector—including cereals, beverages, cheeses, yogurts, eggs, milk, 
margarines, spreads and dressings—has been one of the fastest growing food categories in Europe and 
North America [43]. At present, alternatively to fish oils, some n-3 LC-PUFA-rich single cell oils, 
mostly of microalgal origin, are used in marketed fortified foods. Recently, the health risks and side 
effects posed by n-3 LC-PUFA consumption from various sources were reviewed [37]. Fish oil 
supplementation was investigated using several delivery methods (capsules, fish-containing meals, 
fortified foods, or parenteral administration) and results from two studies advised caution when 
supplying high dietary n-3 LC-PUFA levels in both type 2 diabetes mellitus patients and individuals 
with impaired glucose tolerance, due to risks of increased glycaemia; algal oils appeared to be well 
tolerated and no major negative effects have been reported, though fishy aftertaste and eructation may 
occur associated to daily consumption of relatively high (2 g) algal DHA doses [37]. 
4. Microalgae Production 
Microalgae offer a promising non-polluted resource for biotechnology and bioengineering of LC-PUFA 
production (Figure 1), as an alternative to fish oils [5,44]. Compared to terrestrial crop plants, 
microalgae present a few advantages as n-3 LC-PUFA sources, such as commonly occurring genes for 
the biosynthesis of these nutrients, simpler fatty acid profiles and higher growth rates. In industrial 
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production, outdoor photoautotrophic technologies for microalgae cultures in open pond systems have 
long been established [45]. Autotrophic microalgal cultivation of marine species in these systems can 
utilize non-arable lands and water resources considered unsuitable for agriculture; these processes also 
have a more favorable net energy ratio, relative to heterotrophic systems, but may suffer from 
unwanted contamination with competitors and predators. Superior growth performance and 
productivity are naturally obtained using (photo) bioreactors, which present the advantage to provide 
close control over growth conditions, but imply greater investments related, for example, with  
energy-dependent expenditures for mixing and cooling. The use of these sophisticated systems is 
particularly justified regarding high-value products, which are not obtainable in desired quality or 
quantity from other sources [46]. Heterotrophic cultivation without light, using inexpensive, well-defined 
mineral medium supplemented with a carbon source is feasible [46]. However, only a few species have 
been commercially explored and continuous efforts are made in order to diversify the range of 
microalgal species used [47]. This implies fermentation studies for growth medium optimization, and 
improvement of culture conditions and systems, in order to maximize the biosynthesis of n-3 LC-PUFA in 
each potential strain [48,49]. 
Figure 1. Schematic representation of benefits related with dietary intake of n-3 LC-PUFA, 
obtained by extraction of the oil from marine plankton. 
 
Briefly, in order to be selected for commercial oil production with human consumption purposes, 
microalgae and their products should be non-pathogenic and non-toxic, genetically stable, and present 
high growth and product formation rates, as reviewed by Ward and Singh [6]. Ideally, for edible oil 
production, strains used should be capable of accumulating significant amounts of lipids, preferably 
rich in TAGs high in the LC-PUFA of interest, under heterotrophic or autotrophic growth. The ability 
to use low-cost fermentation media and growth in low chloride, which has corrosive properties on 
stainless steel vessels, is also desirable [6]. 
5. Microalgae as Sources of n-3 LC-PUFA 
In the marine food web, long-chain polyunsaturated fatty acids (≥20 carbon atoms and >3 double 
bonds) are primarily formed by phytoplankton and transferred onto herbivorous zooplankton, hence 
affecting food quality for organisms at higher trophic levels [50]. Various auto- and heterotrophic 
marine species from different classes produce EPA and DHA, whereas AA is generally found in scarce 
amounts [51,52]. According to recent reviews of total lipid extracts, Bacillariophyceae (diatoms) and 
Chrysophyceae species may be rich sources of EPA and DHA; Cryptophyceae, Prasinophyceae, 
Rhodophyceae, Xanthophyceae, Glaucophyceae and Eustigmatophyceae can represent interesting EPA 
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sources, whereas DHA is found in significant amounts mostly in Dinophyceae, Prymnesiophyceae, and 
Euglenophyceae [53,54]. Interestingly, many species producing LC-PUFA contain low levels of C18 
fatty acid precursors [5]. The development of commercial processes for microalgal oil production, 
particularly oils rich in DHA, has benefited from the fact that a number of organisms can accumulate 
high lipid contents in biomass (up to 50% biomass dry weight; DW), including 30%–70% of this fatty 
acid [6]. The sector has expanded substantially in recent years and product diversity, in terms of 
growing processes and subsequent fatty acid profiles, is expected to increase, particularly by 
developing ingredients with higher EPA and DHA concentration in the near future [55]. Table 1 lists a 
series of commercially available microalgae oils, including a high-purity, pharmaceutical grade 
product rich in EPA. 
Table 1. Levels of eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) in 
commercially available oils derived from marine microalgae cultures 
1
. 
Company and commercial 
product designation 
% EPA or DHA 
2
 Microbial sources available Comments 
Aurora Algae A2 EPA Pure™ 
65% EPA (regular)  




Qualitas Health EicoOil™ 25%–30% EPA Nannochloropsis oculata Hibberd 
Phototrophic,  
open-pond 
Algae Biosciences AlgaeBio  
Omega-3 Origins™ 
20% EPA; 20% DHA Undisclosed 
Oil blend from two 
marine strains 
DSM-NP life’s DHA™ 40%–45% DHA Crypthecodinium cohnii Javornicky  Heterotrophic 
fermentation DSM-NP life’s DHA plus EPA™ 10% EPA; 22.5% DHA Schizochytrium sp. Goldstein and Belsky 
Lonza DHAid™ 35%–40% DHA Ulkenia sp. Gaertner 
Heterotrophic 
fermentation 
Source-Omega Source Oil™ 35%–40% DHA 
Schizochytrium sp.  
Goldstein and Belsky 
Heterotrophic 
fermentation 
GCI Nutrients DHA Algae  
35% Oil 
35% DHA Crypthecodinium cohnii Javornicky 
Heterotrophic 
fermentation 
1 Information obtained from the respective commercial web sites; 2 % EPA or % DHA (m/m) of commercial oil. 
LC-PUFA biosynthesis from C18 fatty acids, LA and α-linolenic acid (ALA), by the  
elongase-desaturase pathway is common in microalgae [5]. These usual n-6 and n-3 pathways involve 
a desaturation step by Δ6 desaturase, an elongation step and a further desaturation by Δ5 desaturase, 
yielding AA and EPA (Figure 2). As reviewed by Khozin-Goldberg et al. [6], in some species, 
alternative pathways exist for the biosynthesis of AA and EPA, involving elongation of the C18 
precursors, followed by Δ8 and Δ5 desaturation. In microalgae, DHA is obtained through EPA 
elongation into docosapentaenoic acid (DPA) and subsequent desaturation by Δ4 desaturase, or 
through the anaerobic polyketide synthase (PKS) pathway, as it has been suggested for 
thraustochytrids [56] and has been inferred in silico for the coccolithophore Emiliania huxleyi Hay and 
Mohler [4], which are known for their potential to accumulate important amounts of PUFA [57,58]. 
These pathways are different from the metabolic synthesis of DHA found in animals, known to occur 
through the Sprecher’s shunt [59]. 
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Figure 2. Biosynthetic pathways of the long chain polyunsaturated fatty acids (LC-PUFA) 
in marine microalgae (except for the polyketide synthase-dependent pathway that is 
purported to occur in thraustochytrids and coccolithophores). LC-PUFA are painted blue. 
The desaturases and elongases catalyzing a given step are given in red and orange, 
respectively. FAS, fatty acid synthase. Unlike mammals, microalgae seldom accumulate 
high levels of arachidonic acid (AA), as the n-3/∆17 desaturase present in the endoplasmic 
reticulum of these cells converts it to eicosapentaenoic acid (EPA) [5,48,51,60].
 
Under stressful environmental conditions (e.g., nutrient deficiency, photo-oxidative stress) and in 
aging algal cells, microalgae tend to stop growth and accumulate neutral lipids, particularly TAGs, 
which deposit into lipid bodies and are thought to serve as carbon and energy storages for usage under 
starvation [51,53]. Microalgae species considered oleaginous contain at least 20% lipid of their 
biomass, and levels can range up to 70% with TAGs accounting for over 90% of the total lipid [53,61]. 
However, TAGs are usually high in saturated and monounsaturated fatty acids (MUFA) [62], hence, 
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partitioning of LC-PUFA into TAGs is seldom found. EPA, for example, does not generally 
accumulate significantly in neutral lipid except in some obligate phototrophic microalgae [44]. 
Usually, LC-PUFA in microalgae are esterified into membrane phospholipids [53], while it is 
generally thought that esterification into TAGs would provide a more suitable dietary source for the 
human diet. However, some species may show significant amounts of LC-PUFA esterified into TAG, 
like DHA in Thraustochytrium aureum Goldstein [63], and AA and EPA in the red alga  
Porphyridium cruentum Nägeli [64]. Culture conditions, strains used and growth phase are important 
determinants of LC-PUFA production and partition into TAGs. Tonon et al. [65] described the 
influence of growth stages on EPA and DHA deposition in TAG extracts in several species. They 
found a higher percentage of EPA in TAGs of Nannochloropsis oculata Hibberd, and of both EPA and 
DHA in TAGs of Thalassiosira pseudonana Hasle and Heimdal and Pavlova lutheri Green during the 
stationary phase. In order to increase microalgae usage for commercial production of LC-PUFA-rich 
oils, research efforts are directed to the screening and selection of oleaginous microalgal species with 
the capacity to store LC-PUFA in TAGs, which would allow for more cost-effective production of oil 
and could also facilitate lipid extraction. 
5.1. Photoautotrophic Microalgae 
It is generally thought that photosynthetic microalgae tend to produce higher levels of EPA than 
heterotrophs. Nannochloropsis Hibberd, Phaeodactylum Bohlin, Nitzschia Hassall and Porphyridium 
Nägeli can present elevated levels of EPA in total fatty acids, although relatively low cell lipid 
contents tend to result in small EPA amounts in the biomass (Table 2). Photoautotrophic species 
contain lipids involved in the photosynthetic metabolism and, unlike various DHA-rich microalgae, the 
fatty acid profiles of EPA producers usually show other LC-PUFA, like DHA and/or AA [61]. 
Phototrophic species, such as the eustigmatophyte Nannochloropsis, have long been used by the 
aquaculture industry with the aim to supply larval fish with n-3 LC-PUFA through the enrichment of 
live feeds (e.g., rotifers). In a recent report, Gog et al. [66] described a Nannochloropsis oculata with a 
fatty acid profile containing 49% of EPA of total fatty acids, while most commonly Nannochloropsis 
strains show lower levels, in the range of 11%–39% of total fatty acids, varying largely with 
cultivation conditions (Table 2), particularly nitrogen supply [67,68]. Although Nannochloropsis 
accumulates TAGs in response to environmental stressors, EPA deposition may be low within this 
lipid class [69], which is instead associated with shorter fatty acids [70]. Deposition of EPA in 
Nannochloropsis seems to be favored by low salinity [68], while total lipids appear to increase in 
higher salinity waters [69]. The cultivation of Nannochloropsis sp. in ultra-dense cultures, with 
valuable EPA production, using frequent replacement of nutrient medium, has been described [71]. In 
fact, the genus Nannochloropsis is currently the source of marketed oils due to its potential to produce 
high EPA lipids with very low DHA and AA content, which is advantageous for the manufacture of 
dietary supplements (Table 1). 
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Table 2. Examples of marine microalgae species characterized by EPA production. 
Species EPA content (% TFA) 
1 





38–39 2–3 [72] 
15–18 5–6 [73] 
11–22 3–6 [74] 
15–27 4 [75] 
5–27 2–4 [69] 
30–35 3–4 Soley Biotechnology Institute 3 
35–39 4 Soley Biotechnology Institute 3 
Phaeodactylum 
tricornutum Bohlin 
31 5 [76] 
40–57 1–4 [77] 
28 3 [78] 
30–32 3 Soley Biotechnology Institute 3 
38–42 4–5 Soley Biotechnology Institute 3 
Nitzschia laevis Hustedt 25–33 3–4 [79] 
11–16 2–3 [80] 
Porphyridium cruentum 
Nägeli 
25 3 [81] 
41 - [82] 
Odontella aurita Agardh 26 - [83] 
Pavlova lutheri Green 
18–23 - [83] 
22–29 - [84] 
Cyclotella cryptica 
Lewin and Guillard 
17–23 1 [85] 
Cylindrotheca sp. 
Rabenhorst 
24–25 - [86] 
1 % TFA, % of total fatty acids; 2 % DW, % of biomass dry weight; 3 Data obtained from the commercial web site. 
The diatom Phaeodactylum tricornutum Bohlin is often known for its high EPA content in total 
fatty acids (Table 2). Differences in preferential deposition of this fatty acid either in TAGs or in polar 
lipids reflect the importance of cultivation conditions. For example, under optimal conditions tested in a 
continuous flow reactor, 84% of this fatty acid was found in galactolipids (monogalactosyldiacylglycerols) 
and 11% EPA in TAGs [87], whereas another experiment varying nitrogen concentration and culture 
age showed TAGs as the most important EPA reservoir in cells [88]. As EPA is mostly found in the 
less polar lipid fractions displaying very favorable EPA/AA and EPA/eicosatetraenoic acid ratios,  
Reis et al. [87] suggested that purification of this FA from P. tricornutum biomass should be simpler 
than from other feedstock. Moreover, being amenable to genetic engineering, P. tricornutum could be 
transformed with a glucose transporter gene, allowing the cultivation of this microalga in high cell 
concentrations under heterotrophic conditions [89]. 
Another potential EPA producer is Nitzschia laevis Hustedt, a diatom that can be grown 
heterotrophically using glucose and was reported to synthesize more EPA through this process than 
photosynthetically [90]. Under heterotrophic cultivation, according to Chen et al. [91], this microalga 
can present about 80% neutral lipids of total fatty acids, of which 88% as TAGs. However, only about 
6% EPA was determined in the total fatty acids of this lipid fraction. These authors found in a 
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subsequent study that temperature did not affect lipid class proportions, lipid and EPA contents, and 
reported that TAGs were highly saturated in this species [92]. 
On the other hand, the red microalga Porphyridium cruentum can present 41% EPA of total fatty 
acids although TAGs appear to represent a minor proportion of all lipid classes (2%) [82]. Some 
studies have focused on the suitability of this species as a source of highly pure EPA, using various 
extraction processing and purification protocols [93,94]. Another potential source of EPA-rich oils is 
the diatom Odontella aurita Agardh, which may contain around 26%–28% EPA in its fatty acid  
profile [94] and is currently approved for use as a food supplement [95], which could facilitate the 
acceptance of the oil as an ingredient in the market. 
Much research on optimization of EPA and lipid production has been conducted at relatively low 
cell concentrations, in contrast with those needed to support an economical production. As mentioned 
previously, mass cultivation of phototrophic species in open-pond systems is a relatively low cost 
system compared to photobioreactors. However, specific growth rates in these systems are relatively 
low, harvesting may be costly, and the risks of salinity fluctuation and contamination can lead to 
variable quality and quantity of the final product [96,97]. Cultivation of autotrophic organisms in 
photobioreactors with high volume to surface ratios is currently limited due to light penetration 
restrictions, but provides optimized control over environmental parameters, significantly reduces 
contamination risks, and allows higher biomass concentrations [96]. Overall, application of 
photosynthetic species for the commercial production of oils requires advances in physiological and 
genetic engineering studies to enhance growth performances and lipid deposition, optimization of fatty 
acid composition, biotechnological improvements regarding light capture and contamination, and 
lowering of costs involved in biomass production and harvesting [5]. 
5.2. Heterotrophic Microalgae 
Several marine heterotroph microalgae are considered as good DHA sources (Table 3). These 
include thraustochytrids from the genera Thraustochytrium Sparrow and Schizochytrium Goldstein and 
Belsky, and the dinoflagellate Crypthecodinium cohnii Javornicky, which have the advantage to 
deposit very low or no EPA in cell lipids [61]. These species represent the most preeminent alternative 
industrial sources of oils rich in DHA (Table 1), with approved use in human foods, especially for 
application in infant formulas [61,98], since they are considered to be non-pathogenic and 
nontoxigenic [99]. 
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Table 3. Examples of marine microalgae species characterized by DHA production. 
Species DHA content (% TFA) 
1 
DHA content (% DW) 
2 
References 
Schizochytrium mangrovei Raghuk  31–41 12–21 [100] 
Schizochytrium limacinum Honda 
and Yokochi 
25–35 5–15 [101] 
- 15–19 [102]  
Schizochytrium sp. (HX-308) 
Goldstein and Belsky 
40–56 11–20 [103]  
Schizochytrium sp. Goldstein  
and Belsky 
45–52 20–24 [104] 
28 4 [100]  
Thraustochytrium sp. Sparrow 23–24 16–17 [105] 
Thraustochytrium aureum 
Goldstein 
32–37 6–7 [106]  
Thraustochytrium striatum 
Schneider 
37 2 [100]  
Ulkenia sp. Gaertner  10–23 5 [107]  
Aurantiochytrium sp. Yokoyama 
and Honda 
40 18 [108] 
Crypthecodinium cohnii Javornicky 
19–34 2–4 [109] 
63 6 [110] 
53–57 5–6 [111] 
1 % TFA, % of total fatty acids; 2 % DW, % of biomass dry weight. 
Ward and Singh [6] reported that certain Schizochytrium strains might produce levels as high as 
94% DHA of total n-3 fatty acids. In addition, Schizochytrium sp. has been noted for high resistance to 
mechanical stirring in fermenter culture [112] and high salinity tolerance [113]. Schizochytrium sp. 
possesses a number of traits that are advantageous for the industry, including high lipid content, 
elevated DHA production and presentation in the TAG form, as well as good growth in culture under 
elevated cell concentrations [6]. Nakahara et al. [112] reported that in Schizochytrium sp. containing 
about 50% lipids of biomass dry weight, TAGs represented the majority of lipids (93%, m/m) and that 
57% of TAGs contained DHA, which accounted for 34% of total fatty acids. Under culture conditions 
varying carbon, nitrogen and glucose levels in the medium, Yaguchi et al. [114] described lipid levels 
of 78% (mostly neutral, 95%), and 36% DHA of total fatty acids. In Schizochytrium limacinum Honda 
and Yokochi, DHA levels ranged from 34% to 44% of total lipids, along with smaller levels of DPA 
(5%–7%); higher DHA deposition in TAGs (32%) than in polar lipids was observed at the end of a 10-day 
culture, though mainly due to drastic decrease in DHA in phospholipids, from 62% to 9% of total fatty 
acids at day 1 and day 10, respectively [115]. In addition, Schizochytrium mangrovei Raghuk harvested 
during the exponential phase showed elevated amounts of neutral lipids (96%) with 97% TAGs, in 
which 30% was DHA [116]. 
An evaluation of various extraction methods using Thraustochytrium sp. showed that these 
organisms are capable to contain over 70% lipids of their dry biomass, including 17% DHA in dry cell 
weight [105], which makes them ideal for industrial production of DHA-rich oils, as demonstrated in 
Table 1. Thraustochytrium aureum Goldstein was reported to contain TAGs as the main lipid class and 
to present 40% DHA in total lipids, although cells of this species tended to aggregate in fermenter 
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systems [63]. In a strain of this species, lipid, TAG and PUFA contents appeared to reach the highest 
values during the early phase of cell growth, with DHA representing about 10% of total lipids [117]. 
Huang et al. [118] described a Thraustochytrium sp. strain containing 52% of total fatty acids as DHA, 
as well as other LC-PUFA (AA, EPA, n-6 DPA), which accounted for a total of 76% of total fatty acids. 
Ulkenia sp. Gaertner, another thraustochytrid, is currently used as a commercial source of  
DHA-rich TAG oil, which may contain up to 50% DHA and also includes 8%–14% n-6 DPA [119]. A 
native Thraustochytrid strain with high similarity to Ulkenia sp. showed DHA levels of 10%–24% in 
total fatty acids [107]. 
Ulkenia sp. and Schizochytrium sp. have been considered as much faster growers than 
Thraustochytrium sp. [120], which may be the reason underlying the apparent preferential utilization 
of the former two in industrial oil production (Table 1). The occurrence of n-6 DPA in lipids of these 
three species [112,113], though in much lower amounts than DHA, was initially seen as a disadvantage 
for commercial purposes, especially for neonate nutrition applications [59]. The FDA has considered 
that, since both n-3 and n-6 DPA are natural components of fish oil, their safety is supported by studies 
reporting no adverse effects following supplementation with fish or marine oils [119]. It appears that 
this fatty acid exists naturally in the phospholipids of human cellular membranes [121] and may be 
retroconverted into AA when dietary supply of the latter is low, as well as contribute for the 
maintenance of AA when DHA is administered [122]. Thus, inclusion of DPA into the AA + DHA 
supplements used in infant formulas could actually increase their nutritional value, and these species 
may provide such suitable oils [61]. 
The dinoflagellate Crypthecodinium cohnii has been used in the commercial production of DHA-rich 
oils, particularly for inclusion in infant formulas due to its low EPA content, which in high levels can 
induce bleeding in both infants and nursing mothers [6]. High biomass concentrations in carbon fed 
batch cultures of C. cohnii required prolonged culture times initially, although commercial strains have 
been selected for rapid growth and acceptable DHA productivities, under high cell concentrations and 
high shear conditions, with oil production being promoted by nitrogen-deficient conditions  
(reviewed by Ward and Singh [6]). However, Pleissner et al. [109] reported that nutrient limitation 
(carbon, nitrogen and phosphorus) had no effect on lipid deposition in this species (12%–15%), 
although wide variations on DHA amounts in total fatty acids were detected (19%–34%). An increase 
in DHA productivity could result from the use of carbon sources other than glucose, such as acetate or 
ethanol, though this might imply higher costs and handling challenges (reviewed by Ward and  
Singh [6]). In a pH-auxostat culture using sodium acetate as the main carbon source, lipid 
accumulation in excess of 40% was observed, with DHA as half of the total fatty acids found in  
TAGs [123]. Mendes et al. [124] reported DHA levels up to 63% of total fatty acids using carob pulp 
syrup and yeast extract as carbon and nitrogen sources, respectively, in the culture medium. However, 
using a supercritical carbon dioxide lipid extraction method, it was demonstrated that DHA contents 
could be higher than 72% of total fatty acids [125]. Seemingly, few studies have focused on the 
distribution of DHA among lipid classes in C. cohnii. Apparently, this subject is controversial since 
results vary considerably in the literature [126]. Nonetheless, data related to the industrial production of 
derived oil mention that 30%–50% DHA is generally presented in TAGs and that these represent about 
70% of the extracted oil [32]. 
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Under fermentation, biomass production, lipid composition and DHA yield are generally affected 
by growth medium composition and other factors, like temperature and salinity [49]. However, the use 
of fermenters allows for a tight control over these variables, hence allowing the production of high 
quality commercial oils with better market deliverance guarantees [127]. Other advantages of 
cultivating organisms in fermenters relate to the ease of product recovery, and protection against 
weather conditions and diseases, as mentioned previously; but these systems also require the addition 
of rich media, and productivities are conditioned by the low growth rates of most organisms  
cultivated [96]. Currently, marketed microalgal DHA-rich oils derive from yet too few species. 
Nonetheless, heterotrophic microalgae grown in conventional fermenters without the need for light are 
typically more economic to produce and yield higher biomass than photosynthetic algae cultures [46]. 
5.3. Extraction and Quantification of PUFA in Microalgae 
Fatty acid methyl esters (FAME) are commonly assessed by GC-MS (gas chromatography coupled 
with a mass spectrometry detector) or GC-FID (gas chromatography coupled with a flame ionization 
detector). However, prior to analysis, lipids must be extracted from microalgal cells, which is a crucial 
step in the FAME quantification process. For this extraction, there are several well defined procedures 
including the Bligh & Dyer [128] method and/or Soxhlet extraction. However, these methods have 
been developed for non-photosynthetic matrices. Microalgae normally possess a thick cell wall, which 
needs to be disrupted to allow an efficient extraction of lipids otherwise the yield of the lipid extraction 
may be seriously compromised. This can be achieved by submitting microalgae cells to 
homogenization with dispersers (e.g., IKA Ultra-Turrax), or other methods that may involve sonication, 
microwaves, thermolysis, bead-beating, among others [129]. After extraction, the fatty acids must 
undergo derivatization during which the carboxylic acids are converted into methyl or ethyl esters. 
This step is needed before GC analysis in order to improve volatility of the fatty acids and achieve 
better resolutions in the chromatographic procedure [130]. There are several types of derivatization 
described in the literature, which can be applied to samples of microalgae, such as alkali- and  
acid-catalyzed transesterification. Previous reports, however, have demonstrated that the use of  
acid-catalyzed esterification using methanol and acetyl chloride are the most adequate for the typical 
PUFA usually found in microalgal samples [131]. Upon derivatization, the identification and 
quantification of PUFA (or any other FAME) is performed in the same way as for lipids from different 
sources. However, care must be taken that the PUFA profile does not change during the isolation 
procedure, as it has been shown that in a few diatoms EPA can become depleted if the enzymatic 
activity is not inhibited by acidification prior to cell disruption [132]. 
6. Future Perspectives and Conclusion 
Recent opinion suggests that EPA and DHA should be considered as conditionally essential for 
humans [133]. The development of an efficient large-scale cultivation system for the commercial 
production of these nutrients from microalgae would address a major global need [7]. The market for 
these oils is at the moment limited by supply, hence isolation and exploitation of strains with important 
n-3 LC-PUFA production potential is on-going [47]. Since the microbial route of oil production 
through fermentation will always be more costly than potential agricultural alternatives  
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(i.e., genetically modified crops), continuous efforts must be made in the sense of reducing production 
costs while focusing on high-value products with applications in human health [61]. Consumers are 
aware of the importance of an adequate provision of these nutrients and several properties of 
microalgal oils are particularly appealing, such as their sustainability, high purity and quality, 
“vegetarian” origin, and improved organoleptic qualities when compared to fish oils. Although the use 
of genetically modified microalgae by the industry is regarded as a possibility in the process of 
developing strains producing tailored oils [48], this may, as in other sectors of food production, 
encounter major opposition from the public opinion. Although genetically modified crops will likely 
serve as n-3 LC-PUFA sources in the future, microalgae oils have a great potential to present purer 
profiles, which are highly advantageous during processing and may address differentiated purposes in 
the market. 
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